NSW Government grant for UNSW collaboration

Highlights

- **Joint project with UNSW Sydney**
- **Early-stage feasibility study**
- **Versatile Sofra™ technology potential**

Sydney, 11 November 2025: Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the awarding of a TechVoucher grant for a joint project with UNSW.

The NSW Government's TechVouchers program funds collaborative research projects between SMEs and researchers. It is designed to support the translation of knowledge and inventions to new products and services.

A team at UNSW Sydney will use the $25,000 TechVoucher funding to explore how Noxopharm's novel anti-inflammatory oligonucleotides from the Sofra™ technology platform could be used to reduce the inflammation caused by implants.

This is an early-stage study to assess the feasibility of the concept, and Noxopharm will provide matched funding to support the initiative.

Noxopharm CEO Dr Gisela Mautner said: "This grant is another illustration of the potential of our technology which, because of its ability to mitigate inflammation, could one day be used in a wide variety of settings.

"UNSW has been a longstanding collaborator, and we are very much looking forward to benefiting from their expertise and insights as this study progresses."

-ENDS-

About the Sofra technology platform

Developed from a breakthrough discovery in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines.

Sofra technology has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease.

Further information and animations: SOF-SKN / SOF-VAC

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.